NeoTCR-P1 adoptive cell therapy (PACT Pharma)

N/A

Report date: 2022/08/19 20:00:31

Base Information

Drug NameNeoTCR-P1 adoptive cell therapy (PACT Pharma)
Drug Alias NameGene edited Autologous NeoTCR-T CellsNeoTCR-P1
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPact Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPact Pharma Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A